ArticlePloS one2011
Impact of CD1d deficiency on metabolism.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 85 citations in OpenAlex.
- CD1 molecules: Beyond antigen presentation.Molecular immunology · 2024Review
- The PD-1/PD-L1 Axis in the Biology of MASLD.International journal of molecular sciences · 2024Review
- Contribution of NKT cells and CD1d-expressing cells in obesity-associated adipose tissue inflammation.Frontiers in immunology · 2024Review
- Effects of NKT Cells on Metabolic Disorders Caused by High-Fat Diet Using CD1d-Knockout Mice.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Article
- A comparative study on roles of natural killer T cells in two diet-induced non-alcoholic steatohepatitis-related fibrosis in mice.Annals of medicine · 2022Article
- CD1d-dependent rewiring of lipid metabolism in macrophages regulates innate immune responses.Nature communications · 2022Article
- Resident and migratory adipose immune cells control systemic metabolism and thermogenesis.Cellular & molecular immunology · 2022Review
- Immunological mechanisms and therapeutic targets of fatty liver diseases.Cellular & molecular immunology · 2021Review
- Leukocyte Heterogeneity in Adipose Tissue, Including in Obesity.Circulation research · 2020Review
- Article
- The Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obesity.Frontiers in immunology · 2019Review
- Deficiency of Invariant Natural Killer T Cells Does Not Protect Against Obesity but Exacerbates Atherosclerosis in LdlrInternational journal of molecular sciences · 2018Article
- Endogenous lipid antigens for invariant natural killer T cells hold the reins in adipose tissue homeostasis.Immunology · 2018Review
- New Genetically Manipulated Mice Provide Insights Into the Development and Physiological Functions of Invariant Natural Killer T Cells.Frontiers in immunology · 2018Review
- Regulatory Roles of Invariant Natural Killer T Cells in Adipose Tissue Inflammation: Defenders Against Obesity-Induced Metabolic Complications.Frontiers in immunology · 2018Review
- Role of Natural Killer T Cells in the Development of Obesity and Insulin Resistance: Insights From Recent Progress.Frontiers in immunology · 2018Review
- Review
- CD1d-Restricted pathways in hepatocytes control local natural killer T cell homeostasis and hepatic inflammation.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Unusual Suspects in the Development of Obesity-Induced Inflammation and Insulin Resistance: NK cells, iNKT cells, and ILCs.Diabetes & metabolism journal · 2017Review
- Sevelamer Improves Steatohepatitis, Inhibits Liver and Intestinal Farnesoid X Receptor (FXR), and Reverses Innate Immune Dysregulation in a Mouse Model of Non-alcoholic Fatty Liver Disease.The Journal of biological chemistry · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Invariant natural killer T cells (iNKTs) are innate-like T cells that are highly concentrated in the liver and recognize lipids presented on the MHC-like molecule CD1d. Although capable of a myriad of responses, few essential functions have been described for iNKTs. Among the many cell types of the immune system implicated in metabolic control and disease, iNKTs seem ideally poised for such a role, yet little has been done to elucidate such a possible function. We hypothesized that lipid presentation by CD1d could report on metabolic status and engage iNKTs to regulate cellular lipid content through their various effector mechanisms. To test this hypothesis, we examined CD1d deficient mice in a variety of metabolically stressed paradigms including high fat feeding, choline-deficient feeding, fasting, and acute inflammation. CD1d deficiency led to a mild exacerbation of steatosis during high fat or choline-deficient feeding, accompanied by impaired hepatic glucose tolerance. Surprisingly, however, this phenotype was not observed in Jα18⁻/⁻ mice, which are deficient in iNKTs but express CD1d. Thus, CD1d appears to modulate some metabolic functions through an iNKT-independent mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.